2. Immunology/Inflammation
  3. Transmembrane Glycoprotein
  4. HB0030

HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3+ Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors.

For research use only. We do not sell to patients.

HB0030

HB0030 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

HB0030 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3+ Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
In Vitro

HB0030 (10-5-103 nM; 5 hours) potently mediates NK cell-dependent lysis of human TIGIT-expressing Jurkat cells in vitro, with greater cytotoxic activity than HB0036[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HB0030 Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: human TIGIT-expressing Jurkat cells, pre-activated human NK cells
Concentration: 10-5-103 nM
Incubation Time: 5 hours
Result: Mediated dose-dependent NK cell killing of TIGIT-expressing Jurkat cells.
Showed stronger cytotoxic activity compared to HB0036.
In Vivo

HB0030 (500 mg/kg; i.p.; single dose) significantly reduces intratumoral FoxP3+ Treg proportions in hPD-L1+ MC38 tumors in humanized C57BL/6 mice[1].
HB0030 (10 mg/kg; i.p.; twice weekly; 4 total doses) combined with anti-PD-L1 antibody 900458 significantly reduces tumor volume and weight, and increases intratumoral IFN-γ and TNF-α levels, in CT26-hPD-L1 tumor-bearing humanized BALB/c mice[1].
HB0030 (3 mg/kg; i.p.; twice weekly; 4 total doses) monotherapy significantly inhibits H22-hPD-L1 tumor growth with a 50% partial response rate, and its combination with HB0025 enhances efficacy to an 87.5% partial response rate in humanized BALB/c mice[1].
HB0030 (3 mg/kg; i.p.; twice weekly; 4 total doses) combined with HB0025 significantly enhances tumor inhibition compared to monotherapies in hPD-L1-expressing MC38 tumor-bearing humanized C57BL/6 mice[1].
HB0030 (10 mg/kg; i.p.; twice weekly; 4 total doses) combined with HB0025 significantly enhances tumor inhibition compared to monotherapies in hPD-L1-expressing EMT6 tumor-bearing humanized BALB/c mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: hTIGIT/hPD-L1/hPD-1 humanized C57BL/6 (subcutaneously inoculated with 1×106 wild-type hPD-L1- MC38 cells on left flank and 1×106 hPD-L1+ MC38 cells on right flank, grown to ~200 mm3 over 13 days)[1]
Dosage: 500 mg/kg
Administration: i.p.; single dose
Result: Significantly reduced the proportion of FoxP3+ regulatory T cells (Tregs) in tumor-infiltrating lymphocytes within hPD-L1+ MC38 tumors.
No significant Treg reduction was observed in hPD-L1- MC38 tumors.
Animal Model: hPD-1/hPD-L1/hTIGIT humanized BALB/c (subcutaneously inoculated with 1×106 CT26-hPD-L1 cells, grown to average volume of 160 mm3)[1]
Dosage: 10 mg/kg (in combination with 10 mg/kg anti-PD-L1 antibody 900458)
Administration: i.p.; twice weekly; 4 total doses
Result: Significantly reduced tumor volume and tumor weight compared to control.
Elevated intratumoral IFN-γ and TNF-α levels compared to control, though lower than levels in the HB0036 monotherapy group.
Animal Model: hPD-1/hPD-L1/hTIGIT humanized BALB/c (subcutaneously inoculated with 1×106 H22-hPD-L1 cells, grown to average volume of 100 mm3)[1]
Dosage: 3 mg/kg (monotherapy; in combination with 2 mg/kg anti-PD-L1/VEGF bispecific antibody HB0025)
Administration: i.p.; twice weekly; 4 total doses
Result: Showed significant tumor inhibition compared to isotype control, with a partial response rate of 3/6.
Combination with HB0025 showed superior tumor suppression compared to either monotherapy, with a partial response rate of 7/8.
Gene ID

201633  [NCBI]

Accession
Target

TIGIT
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

HB0030 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HB0030HB 0030HB-0030Transmembrane Glycoproteinregulatory T cellsFoxP3+ TregTIGITcomplement-dependent cytotoxicitytumor-infiltrating lymphocytespancreatic adenocarcinomaantibody-dependent cellular cytotoxicityhepatocellular carcinomacolorectal carcinomanatural killer cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
HB0030
Cat. No.:
HY-P992361
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.